Provided by Tiger Trade Technology Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

79.03
+0.56000.71%
Post-market: 79.030.00000.00%19:57 EDT
Volume:270.11K
Turnover:21.38M
Market Cap:6.17B
PE:79.83
High:79.93
Open:78.28
Low:78.01
Close:78.47
52wk High:82.94
52wk Low:32.89
Shares:78.02M
Float Shares:40.19M
Volume Ratio:0.54
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9900
EPS(LYR):0.7500
ROE:14.04%
ROA:8.05%
PB:9.43
PE(LYR):105.37

Loading ...

Kiniksa Pharmaceuticals CSO Resigns and Shifts to Advisor

TIPRANKS
·
May 02

Kiniksa Chief Strategy Officer Eben Tessari resigns to pursue new role

Reuters
·
May 02

Kiniksa CEO Sanj K Patel disposes of 486,339 shares for $25.23 million

Reuters
·
May 01

Kiniksa Pharmaceuticals’ Mine Safety Disclosure: No Incidents Reported but Transparency Gaps Remain for Investors

TIPRANKS
·
Apr 30

Kiniksa director Barry Quart sells 13,099 shares for $656,812.9

Reuters
·
Apr 30

Kiniksa Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Apr 30

Canaccord Genuity Reaffirms Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)

TIPRANKS
·
Apr 29

Kiniksa Pharmaceuticals International Plc : Wells Fargo Raises Target Price to $57 From $53

THOMSON REUTERS
·
Apr 29

Kiniksa Pharmaceuticals Is Maintained at Buy by Jefferies

Dow Jones
·
Apr 29

Kiniksa price target raised to $71 from $58 at Jefferies

TIPRANKS
·
Apr 29

Kiniksa Pharmaceuticals Up Over 20%, on Track for Record High Close -- Data Talk

Dow Jones
·
Apr 29

Wedbush Lifts Price Target on Kiniksa Pharmaceuticals International to $59 From $58, Maintains Outperform Rating

MT Newswires Live
·
Apr 28

Kiniksa rises 16.9%

TIPRANKS
·
Apr 28

Stock Track | Kiniksa Pharmaceuticals Soars 12.74% on Strong Q1 Earnings Beat and Raised Revenue Guidance

Stock Track
·
Apr 28

How Kiniksa’s Shift To Profitability And Higher Revenue At Kiniksa Pharmaceuticals International (KNSA) Has Changed Its Investment Story

Simply Wall St.
·
Apr 28

KNSA Earnings: Kiniksa Pharmaceuticals Stock Surges on Strong Q1 Beats

TIPRANKS
·
Apr 28

Kiniksa publishes corporate presentation on ARCALYST growth in recurrent pericarditis market

Reuters
·
Apr 28

Kiniksa reports Q1 EPS 27c, consensus 16c

TIPRANKS
·
Apr 28

Kiniksa raises FY26 revenue view to $930M-$945M from $900M-$920M

TIPRANKS
·
Apr 28

Kiniksa Pharmaceuticals Q1 EPS $0.27 Beats $0.19 Estimate, Sales $214.300M Beat $206.091M Estimate

Benzinga Earnings
·
Apr 28